Eli Lilly & Co. (NYSE: LLY) reported Q4 EPS of $0.95, $0.02 worse than the analyst estimate of $0.97. Revenue for the quarter came in at $5.76 billion versus the consensus estimate of $5.55 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2017 EPS of $4.05-$4.15, versus the consensus of $4.10.

"Newly launched products - including Trulicity, Cyramza, Jardiance and Taltz - led Lilly's volume-driven growth in 2016. Pipeline progress also continued with approvals of new products and new indications for existing products in our core therapeutic areas of diabetes, oncology and immunology," said David A. Ricks, Lilly's president and CEO. "We expect this momentum to continue in 2017 and remain focused on launching new products, improving productivity and advancing our pipeline as we work to bring life-changing medicines to patients."

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.